癌症治疗：停用BCL-X(L)。 - Suppr

Suppr

超能文献

Cancer therapeutics: Pulling the plug on BCL-X(L).

作者信息

Jeng Paul S, Cheng Emily H

机构信息

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

出版信息

Nat Chem Biol. 2013 Jun;9(6):351-2. doi: 10.1038/nchembio.1256.

DOI:10.1038/nchembio.1256

PMID:23689630

Abstract

摘要

相似文献

Cancer therapeutics: Pulling the plug on BCL-X(L).

Nat Chem Biol. 2013 Jun;9(6):351-2. doi: 10.1038/nchembio.1256.

Structure-guided design of a selective BCL-X(L) inhibitor.

Nat Chem Biol. 2013 Jun;9(6):390-7. doi: 10.1038/nchembio.1246. Epub 2013 Apr 21.

Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.

Curr Top Med Chem. 2007;7(10):961-5. doi: 10.2174/156802607780906843.

Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer.

Recent Pat Anticancer Drug Discov. 2008 Jan;3(1):20-30. doi: 10.2174/157489208783478676.

Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):3946-50. doi: 10.1016/j.bmcl.2012.04.103. Epub 2012 May 2.

Structural insights into mouse anti-apoptotic Bcl-xl reveal affinity for Beclin 1 and gossypol.

Biochem Biophys Res Commun. 2010 Apr 9;394(3):515-21. doi: 10.1016/j.bbrc.2010.03.002. Epub 2010 Mar 4.

Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein.

J Chem Inf Model. 2011 Jun 27;51(6):1249-58. doi: 10.1021/ci100501d. Epub 2011 May 13.

Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1592-5. doi: 10.1016/j.bmcl.2009.02.020. Epub 2009 Feb 8.

Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors.

Org Biomol Chem. 2012 Apr 21;10(15):2928-33. doi: 10.1039/c2ob07125h. Epub 2012 Mar 7.

Targeting Bcl-xL enhances the cytotoxicity of chemotherapeutics.

Cancer Biol Ther. 2008 Jan;7(1):61-2. doi: 10.4161/cbt.7.1.5571. Epub 2008 Feb 11.

引用本文的文献

LOC285629 regulates cell proliferation and motility in colorectal cancer cells.

Clin Transl Oncol. 2018 Jun;20(6):775-784. doi: 10.1007/s12094-017-1788-x. Epub 2017 Nov 2.

Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.

Ecancermedicalscience. 2017 Sep 11;11:767. doi: 10.3332/ecancer.2017.767. eCollection 2017.

Direct Activation of Bax Protein for Cancer Therapy.

Med Res Rev. 2016 Mar;36(2):313-41. doi: 10.1002/med.21379. Epub 2015 Sep 23.

Dynamics of the BH3-Only Protein Binding Interface of Bcl-xL.

Biophys J. 2015 Sep 1;109(5):1049-57. doi: 10.1016/j.bpj.2015.07.043.

Endiandric Acid Derivatives and Other Constituents of Plants from the Genera Beilschmiedia and Endiandra (Lauraceae).

Biomolecules. 2015;5(2):910-42. doi: 10.3390/biom5020910.

本文引用的文献

Structure-guided design of a selective BCL-X(L) inhibitor.

Nat Chem Biol. 2013 Jun;9(6):390-7. doi: 10.1038/nchembio.1246. Epub 2013 Apr 21.

PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Sci Signal. 2013 Mar 26;6(268):ra20. doi: 10.1126/scisignal.2003483.

Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis.

Cell. 2013 Jan 31;152(3):519-31. doi: 10.1016/j.cell.2012.12.031.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.

Targeting the B-cell lymphoma/leukemia 2 family in cancer.

J Clin Oncol. 2012 Sep 1;30(25):3127-35. doi: 10.1200/JCO.2011.37.0981. Epub 2012 May 29.

From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia.

J Clin Oncol. 2012 Feb 10;30(5):554-7. doi: 10.1200/JCO.2011.37.9339. Epub 2011 Dec 19.

BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program.

Science. 2010 Dec 3;330(6009):1390-3. doi: 10.1126/science.1190217.

The landscape of somatic copy-number alteration across human cancers.

Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822.

Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.

Mol Cell. 2009 Nov 13;36(3):487-99. doi: 10.1016/j.molcel.2009.09.030.

The BCL-2 protein family: opposing activities that mediate cell death.

Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59. doi: 10.1038/nrm2308.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验